远程神经病学对急性缺血性卒中替奈普酶门-针时间的影响
该单中心回顾性队列纳入2022年1月1日至2023年4月1日急诊接受替奈普酶治疗的成人急性缺血性卒中患者93例,比较远程神经病学会诊实施前(43例)与实施后(50例)的门-针时间。实施后门-针时间中位数显著缩短(49分钟 vs 34.5分钟,p<0.01),45分钟内给药比例提高(44.2% vs 80.0%,p<0.01)。24小时神经功能改善、出院时神经功能改善及出血转化率两组无显著差异。作者认为远程神经病学服务可缩短替奈普酶给药时间。
要点
- 实施远程神经病学会诊后,替奈普酶门-针时间中位数由49分钟(IQR 40.0-70.0)降至34.5分钟(IQR 23.8-43.0),p<0.01。
- 实施后45分钟内完成门-针给药的患者比例由44.2%升至80.0%(p<0.01)。
- 24小时神经功能改善(58.1% vs 54.0%)、出院时神经功能改善(60.5% vs 62.0%)及出血转化率(7.0% vs 12.0%)两组无显著差异。
- 该研究为单中心回顾性队列,共纳入93例接受替奈普酶治疗的急性缺血性卒中成人患者。
适用人群与场景
- 2022年1月1日至2023年4月1日期间就诊于单中心综合卒中中心急诊、因急性缺血性卒中接受替奈普酶治疗的成人患者。
研究设计与关键结果
- 研究类型:机构审查委员会批准的回顾性队列研究,单中心综合卒中中心,共93例,远程神经病学实施前组43例、实施后组50例,两组基线特征可比。
- 主要终点:门-针时间(患者进入急诊大门至静脉推注纤溶药物)中位数,实施前49分钟(IQR 40.0-70.0)vs 实施后34.5分钟(IQR 23.8-43.0),p<0.01。
- 次要终点:45分钟内门-针时间比例,实施前44.2% vs 实施后80.0%,p<0.01。
- 次要终点:24小时神经功能改善,实施前58.1% vs 实施后54.0%,无显著差异;出院时神经功能改善,实施前60.5% vs 实施后62.0%,无显著差异;出血转化率,实施前7.0% vs 实施后12.0%,无显著差异。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在因急性缺血性卒中接受替奈普酶治疗的患者中,使用远程神经病学服务可显著缩短门-针时间,且神经功能改善或出血转化率无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Intravenous thrombolysis remains the primary treatment for acute ischemic stroke (AIS); however, administration is time sensitive. Teleneurology services have increased in popularity in recent years due to their ability to aid in triaging patients with neurological conditions. Teleneurology services were implemented at this comprehensive stroke center, in August 2023 to aid in streamlining the administration of tenecteplase in AIS patients. Currently, there are no studies assessing whether the implementation of teleneurology services at a comprehensive stroke center influences tenecteplase door-to-needle time. The purpose of this study is to evaluate the difference in door-to-needle times when tenecteplase is administered with versus without a teleneurology consult.
METHODS: This was an institutional review board approved, retrospective cohort study conducted at a single comprehensive stroke center. Adult patients who presented to the emergency department between January 1st, 2022 and April 1st, 2023 were included if they received tenecteplase for the treatment of AIS. The primary outcome was door-to-needle time, defined as the moment the patient first enters the door of the emergency department to the moment the IV bolus of fibrinolytic is administered. Secondary outcomes included the proportion of patients with door-to-needle time within 45 min, neurological improvement at 24 h and discharge, and rate of hemorrhagic conversion.
RESULTS: A total of 93 patients were included with 43 patients in the pre-teleneurology group and 50 patients in the post-teleneurology group. Baseline characteristics were comparable between both treatment groups. The median door-to-needle time was significantly reduced in the post-teleneurology group (49 minutes [IQR, 40.0-70.0] preintervention vs. 34.5 minutes [IQR, 23.8-43.0] postintervention, p < 0.01). For secondary outcomes, the post-teleneurology group had more patients with a door-to-needle time within 45 minutes (44.2% vs. 80.0%, p < 0.01). There was no significant difference in early neurological improvement (58.1% vs. 54.0%), neurological improvement at discharge (60.5% vs. 62.0%), or hemorrhagic conversion (7.0% vs. 12.0%).
CONCLUSION: Among patients who received tenecteplase for the treatment of AIS, there was a significant reduction in door-to-needle time with the use of teleneurology services. There was no difference in neurological improvement or rate of hemorrhagic conversion.
参考来源
- Butler K, Price C, Rzasa K, et al. Effect of teleneurology on door-to-needle times for tenecteplase in acute ischemic stroke. Am J Emerg Med. 2024. PMID: 39383769. doi:10.1016/j.ajem.2024.09.050
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。